TNDM · Tandem Diabetes Care Inc · Webcasts, Transcripts & Audio
$20.07
+2.56 (+14.62%)
At close · Nov 13
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$1.40B
Shares
69.79M
Volume · Nov 13
4.4M
Avg daily vol (3M)
2.21M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Tandem Diabetes Care Inc Webcasts
Earnings calls, investor updates, investor days and conferences for Tandem Diabetes Care Inc (TNDM), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Conference
Investor event
2026-11-19
Tandem Diabetes Care Inc (TNDM) November 19, 2026 Conference
Scheduled
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q3
2026-11-05
Tandem Diabetes Care Inc (TNDM) Q3 2026 Earnings Call Transcript
Positive tone
U.S. pharmacy transition
2027 revenue outlook
Fully closed-loop development
Revenue
$283.69M
▲ 13.8% YoY Diluted EPS
$-0.10
Gross margin
56.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-08-11
Tandem Diabetes Care Inc (TNDM) August 11, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-06
Tandem Diabetes Care Inc (TNDM) Q2 2026 Earnings Call Transcript
Confident tone
Pharmacy / PAYGO transition
Mobi tubeless launch
International expansion
Revenue
$254.56M
▲ 5.8% YoY Diluted EPS
$-0.31
Gross margin
56.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-08
Tandem Diabetes Care Inc (TNDM) June 8, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-07
Tandem Diabetes Care Inc (TNDM) Q1 2026 Earnings Call Transcript
Confident tone
Pharmacy/PayGo transition
New product launches and pipeline
International expansion / direct operations
Revenue
$247.22M
▲ 5.5% YoY Diluted EPS
$-0.30
Gross margin
55.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-19
Tandem Diabetes Care Inc (TNDM) Q4 2025 Earnings Call Transcript
Revenue
$290.38M
▲ 2.7% YoY Diluted EPS
$-0.01
▼ 200% YoY Gross margin
57.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Tandem Diabetes Care Inc (TNDM) Q3 2025 Earnings Call Transcript
Confident tone
Pharmacy reimbursement strategy
Profitability and margin improvement
Product innovation and pipeline
Revenue
$249.25M
▲ 2.2% YoY Diluted EPS
$-0.31
Gross margin
53.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-06
Tandem Diabetes Care Inc (TNDM) Q2 2025 Earnings Call Transcript
Positive tone
Tandem Mobi product momentum
Type 2 diabetes expansion
U.S. commercial performance and pump shipments
Revenue
$240.68M
▲ 8.5% YoY Diluted EPS
$-0.78
Gross margin
52.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-04-30
Tandem Diabetes Care Inc (TNDM) Q1 2025 Earnings Call Transcript
Confident tone
Gross Margin Expansion Path
Pharmacy Channel Access
International Growth and Direct Sales Transition
Revenue
$234.42M
▲ 22.3% YoY Diluted EPS
$-1.97
Gross margin
50.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-26
Tandem Diabetes Care Inc (TNDM) Q4 2024 Earnings Call Transcript
Confident tone
Tandem Mobi pump platform
Type 2 diabetes label expansion
Control-IQ+ algorithm launch
Revenue
$282.65M
▲ 43.6% YoY Diluted EPS
$0.01
Gross margin
55.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-06
Tandem Diabetes Care Inc (TNDM) Q3 2024 Earnings Call Transcript
Confident tone
Type 2 diabetes market opportunity
Tandem Mobi launch and adoption
Renewals momentum
Revenue
$243.97M
▲ 31.4% YoY Diluted EPS
$-0.35
Gross margin
51.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-01
Tandem Diabetes Care Inc (TNDM) Q2 2024 Earnings Call Transcript
Confident tone
Tandem Mobi launch
Control-IQ algorithm
New sensor integrations / CGM partnerships
Revenue
$221.91M
▲ 13.3% YoY Diluted EPS
$-0.47
Gross margin
50.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-02
Tandem Diabetes Care Inc (TNDM) Q1 2024 Earnings Call Transcript
Confident tone
Mobi product launch
Guidance philosophy and conservatism
Pharmacy channel opportunity
Revenue
$191.67M
▲ 13.2% YoY Diluted EPS
$-0.65
Gross margin
49.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-21
Tandem Diabetes Care Inc (TNDM) Q4 2023 Earnings Call Transcript
Confident tone
Tandem Mobi launch
Renewals and customer base growth
International expansion and OUS challenges
Revenue
$196.80M
▼ 10.8% YoY Diluted EPS
$-0.46
Gross margin
47.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-01
Tandem Diabetes Care Inc (TNDM) Q3 2023 Earnings Call Transcript
Revenue
$185.62M
▼ 9.3% YoY Diluted EPS
$-0.51
Gross margin
48.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Tandem Diabetes Care Inc (TNDM) Q2 2023 Earnings Call Transcript
Revenue
$195.92M
▼ 2.2% YoY Diluted EPS
$-0.55
Gross margin
51.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-03
Tandem Diabetes Care Inc (TNDM) Q1 2023 Earnings Call Transcript
Revenue
$169.38M
▼ 3.7% YoY Diluted EPS
$-1.92
Gross margin
48.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-01-10
Tandem Diabetes Care Inc (TNDM) Q4 2022 Earnings Call Transcript
Revenue
$220.50M
▲ 5% YoY Diluted EPS
$-0.25
▼ 256.2% YoY Gross margin
52.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-02
Tandem Diabetes Care Inc (TNDM) Q3 2022 Earnings Call Transcript
Revenue
$204.55M
▲ 13.9% YoY Diluted EPS
$-0.76
▼ 944.4% YoY Gross margin
51.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-03
Tandem Diabetes Care Inc (TNDM) Q2 2022 Earnings Call Transcript
Revenue
$200.26M
▲ 16.3% YoY Diluted EPS
$-0.24
▼ 500% YoY Gross margin
50.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-04
Tandem Diabetes Care Inc (TNDM) Q1 2022 Earnings Call Transcript
Revenue
$175.91M
▲ 24.7% YoY Diluted EPS
$-0.23
Gross margin
51.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-22
Tandem Diabetes Care Inc (TNDM) Q4 2021 Earnings Call Transcript
Revenue
$210.00M
▲ 24.9% YoY Diluted EPS
$0.16
▼ 27.3% YoY Gross margin
54.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-03
Tandem Diabetes Care Inc (TNDM) Q3 2021 Earnings Call Transcript
Revenue
$179.63M
▲ 45.3% YoY Diluted EPS
$0.09
Gross margin
53.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-04
Tandem Diabetes Care Inc (TNDM) Q2 2021 Earnings Call Transcript
Revenue
$172.14M
▲ 57.6% YoY Diluted EPS
$0.06
Gross margin
53.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-05
Tandem Diabetes Care Inc (TNDM) Q1 2021 Earnings Call Transcript
Revenue
$141.04M
▲ 44% YoY Diluted EPS
$-0.08
Gross margin
52.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-24
Tandem Diabetes Care Inc (TNDM) Q4 2020 Earnings Call Transcript
Revenue
$168.06M
▲ 55% YoY Diluted EPS
$0.22
▲ 450% YoY Gross margin
53.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Tandem Diabetes Care Inc (TNDM) Q3 2020 Earnings Call Transcript
Revenue
$123.60M
▲ 30.6% YoY Diluted EPS
$-0.15
Gross margin
52.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-07-30
Tandem Diabetes Care Inc (TNDM) Q2 2020 Earnings Call Transcript
Revenue
$109.24M
▲ 17.1% YoY Diluted EPS
$-0.45
Gross margin
49.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-04-30
Tandem Diabetes Care Inc (TNDM) Q1 2020 Earnings Call Transcript
Revenue
$97.93M
▲ 48.4% YoY Diluted EPS
$-0.25
Gross margin
51.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-24
Tandem Diabetes Care Inc (TNDM) Q4 2019 Earnings Call
Revenue
$108.40M
▲ 42.3% YoY Diluted EPS
$0.04
▲ 100% YoY Gross margin
55.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–31 of 31 webcasts
Key facts
CIK
1438133
CUSIP
875372203
13F (30d)
215 filings
190 filers
Visit website
Investor relations